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Abstract
Background: Dendritic cells (DC) linking innate and adaptive immune responses are present in human lungs, but
the characterization of different subsets and their role in COPD pathogenesis remain to be elucidated. The aim of
this study is to characterize and quantify pulmonary myeloid DC subsets in small airways of current and ex-
smokers with or without COPD.
Methods: Myeloid DC were characterized using flowcytometry on single cell suspensions of digested human lung
tissue. Immunohistochemical staining for langerin, BDCA-1, CD1a and DC-SIGN was performed on surgical resection
specimens from 85 patients. Expression of factors inducing Langerhans-type DC (LDC) differentiation was evaluated
by RT-PCR on total lung RNA.
Results: Two segregated subsets of tissue resident pulmonary myeloid DC were identified in single cell
suspensions by flowcytometry: the langerin+ LDC and the DC-SIGN+ interstitial-type DC (intDC). LDC partially
expressed the markers CD1a and BDCA-1, which are also present on their known blood precursors. In contrast,
intDC did not express langerin, CD1a or BDCA-1, but were more closely related to monocytes.
Quantification of DC in the small airways by immunohistochemistry revealed a higher number of LDC in current
smokers without COPD and in COPD patients compared to never smokers and ex-smokers without COPD. Impor-
tantly, there was no difference in the number of LDC between current and ex-smoking COPD patients.
In contrast, the number of intDC did not differ between study groups. Interestingly, the number of BDCA-1+ DC
was significantly lower in COPD patients compared to never smokers and further decreased with the severity of
the disease. In addition, the accumulation of LDC in the small airways significantly correlated with the expression
of the LDC inducing differentiation factor activin-A.
Conclusions: Myeloid DC differentiation is altered in small airways of current smokers and COPD patients resulting
in a selective accumulation of the LDC subset which correlates with the pulmonary expression of the LDC-inducing
differentiation factor activin-A. This study identified the LDC subset as an interesting focus for future research in
COPD pathogenesis.
Background
C h r o n i cO b s t r u c t i v eP u l m o n a r yD i s e a s e( C O P D )i s
characterized by destruction of alveolar walls (emphy-
sema) and obstructive bronchiolitis resulting in a pro-
gressive airflow limitation that is not fully reversible [1].
In industrialized countries, cigarette smoke is the most
frequently encountered risk factor for the development
of COPD. Currently, COPD is the fourth leading cause
of death worldwide and according to the World Health
Organization (WHO), mortality will further increase in
the next 20 years [2,3]. The exact pathogenetic mechan-
isms of continuing destructive inflammation in this dis-
ease are not completely understood. Several studies
identified the important role of the activated innate
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neutrophils and macrophages as major effector cells,
inducing tissue destruction by proteolysis and oxidative
stress [4-6]. Other studies addressed the role of the
adaptive immune response in COPD, with increased
numbers of lymphoid follicles and the presence of cyto-
toxic CD8+ T cells and B cells, reflecting a sustained
immune response, even after smoking cessation [7-10].
Dendritic cells (DC) form the crucial link between the
innate and adaptive immunity. Immature DC form a
network in the different layers of the airway mucosa,
specialized in internalizing antigens. Upon recognition
of antigen in the context of a pathogen- or damage-
associated danger signal, DC undergo a maturation pro-
cess and migrate towards the draining lymph nodes.
Mature DC present the processed antigen on Major His-
tocompability Complex (MHC) molecules and interact
with naïve T lymphocytes to form an immunological
synapse, selecting T cells that will target the presented
antigen with specialized effector functions. In this key
position, DC are able to orchestrate the nature and
magnitude of the adaptive immune response to different
antigens [11,12].
Several groups already identified different subsets of
DC in the human lung, mainly using antibodies against
epitopes also present on circulating blood DC (such as
Blood Dendritic Cell Antigen (BDCA) 1-4 and CD11c)
[13-16]. However, no flowcytometric data are available
about pulmonary tissue-resident myeloid DC, such as
Langerhans-type DC (LDC) and Interstitial-type DC
(intDC), two major DC subsets that are well character-
ized in the skin. In general, LDC are identified by the
C-type lectin langerin (CD 207) and the presence of Bir-
beck granules. They are mainly localized in the epithe-
lium, and are involved in activating cellular/cytotoxic
immune responses. IntDC are identified by the C-type
lectin DC-SIGN (Dendritic Cell-Specific Intracellular
adhesion molecule-3-grabbing Non-integrin, CD 209),
are localized in the subepithelial layers and are known
to activate humoral immune responses [17]. CD34+
stem cells and monocytes are known precursors of LDC
and intDC [18,19]. In addition, in vitro studies have
shown that BDCA-1+ CD1a+ blood DCs are the direct
precursors of LDC [20].
Evidence from experimental mouse models suggests a
role for DC in the pathogenesis of COPD [21]. Recently,
we showed that LDC accumulate in the small airways of
patients with COPD [22], while others reported a
decreased number of electronmicroscopic defined DC in
bronchial biopsies of smoking COPD patients [23]. In
contrast, Verhoeven et al and a recent study by Tsou-
makidou et al found no differences in CD1a positive
DCs in bronchial biopsies and small airways of COPD
patients compared to asymptomatic smokers [24,25].
Importantly, several studies indicated that smoking as
such could alter the numbers of DCs in the lung
[26-28].
In this study, we aimed to identify and characterize
tissue resident pulmonary LDC and intDC, investigating
the interrelationship of different myeloid DC markers
such as langerin, BDCA-1, BDCA-3, CD1a and DC-
SIGN. In addition, we aimed to quantify immature mye-
loid DC in small airways of never smokers and smokers
with or without COPD, taking into account whether
they were current or ex- smokers. Finally, we examined
the pulmonary expression of factors such as activin-A
[29], Notch ligand Delta-1 [30], RANK-ligand [31] and
interleukin 15 [32], known from in vitro studies to mod-
ulate the differentiation process of monocytes towards
myeloid DC.
This study shows the presence of two segregated mye-
loid tissue resident pulmonary DC populations: the
intDC and the LDC. In the small airways of current
smokers without COPD and in COPD patients, there is
a selective accumulation of the LDC subset correlating
with the pulmonary expression of the LDC inducing dif-
ferentiation factor activin-A. This evidence is compatible
with an altered differentiation process of myeloid DC in
the small airways and identifies the LDC as an impor-
tant focus for future research in COPD pathogenesis.
Methods
Lung tissue
Lung tissue was obtained from surgical lung resection
specimens of patients diagnosed with solitary pulmonary
tumours at the Ghent University Hospital. Lung tissue
at maximum distance from the pulmonary lesion and
without signs of retro-obstructive pneumonia or tumour
invasion was collected by a pathologist. None of the
patients operated for malignancy were treated with neo-
adjuvant chemotherapy. Lung tissue from end-stage
COPD was obtained from explant lungs from patients
undergoing lung transplantation (University Hospital
Gasthuisberg, Leuven, Belgium). The study population
from which tissue was obtained partially overlaps with
and extends the one described in our previous study
[22]. All patients signed informed consent prior to sur-
gery and were interviewed about their smoking habits
and medication use. Patients were classified as ex-smo-
kers when they had quit smoking at least 1 year prior to
surgery. COPD diagnosis and severity was defined using
pre-operative spirometry according to the GOLD classi-
fication [1]. This study was approved by the Medical
Ethical Committees of the Ghent University Hospital
and the University Hospital Gasthuisberg Leuven.
Between the year 2002 and 2008, small tissue blocks
from the peripheral lung tissue of 85 patients were
stored for immunohistochemical analysis. Samples were
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Zoeterwoude, the Netherlands), snap-frozen in liquid
nitrogen cooled isopentane and stored at minus 80° Cel-
sius. Other samples from the same specimen were fixed
in paraformaldehyde 4% (Sigma, Bornem, Belgium) dur-
i n g1 2h o u r sa n de m b e d d e di np a r a f f i nw a x .I n4 4o f
the 85 patients, RNA was extracted from a part of the
resection specimen which was stored in RNA stabilizing
agent (RNAlater, Qiagen, Hilden, Germany) at minus
80° Celcius. At the moment of designing the PCR
experiments in total lung RNA, a set of 11 RNA samples
from new subjects (not present in the immunohisto-
chemical study) was additionally included.
Flowcytometry
In a separate study, the lung tissue sample from 6 indi-
vidual cases (included in 2008-2009) was processed to
obtain single cell suspensions for flowcytometry as
described previously [13]. There was no overlap between
the subjects in the flowcytometric study and the immu-
nohistochemical study. Single cells were pre-incubated
with human IgG to reduce non-specific binding. Mono-
clonal antibodies used are FITC conjugated anti-human
CD3 (clone UCTH1) and CD19 (clone HIB19), PERCP
conjugated anti-HLA-DR (clone L243), APC conjugated
anti- human CD14 (clone M5E2) and PE or APC conju-
g a t e da n t ih u m a nD C - S I G N( c l o n eD C N 4 6 )( a l lf r o m
BD Biosciences, Erembodegem, Belgium). PE conjugated
anti-human langerin (CD207, clone DCGM4) was pur-
chased at Immunotech-Beckman-Coulter, Marseille,
France. Anti-human biotinylated CD1a (clone HI149)
was purchased at eBioscience, San Diego, CA. APC con-
jugated anti human BDCA-1 (CD1c, clone AD5-8E7),
BDCA-2 (CD303, clone AC141), BDCA-3 (CD141, clone
AD5-14H12) and BDCA-4 (CD304, clone AD5-17F6)
were purchased at Miltenyi Biotec, Bergisch Gladbach,
Germany. APC conjugated anti-human CD163 was pur-
chased at R&D systems, Abingdon, UK. PERCP conju-
gated streptavidin was purchased at BD Biosciences,
Erembodegem, Belgium. Appropriate monoclonal anti-
bodies for isotype control staining were used.
Flowcytometric data acquisition was performed on a
FACS Calibur equipped with 488 and 633 nm lasers and
running Cellquest Software (Becton Dickinson, San
Diego, CA, USA). Flowjo software was used for data
analysis (Treestar, OR, USA).
Histology
7 μm thick cryosections were cut on poly-L-lysine-
coated microscopic slides (Sigma, Bornem, Belgium).
Sections were dried for 24 hours and stored at minus
80° Celsius until use. Prior to the immunohistochemical
procedure, cryosections were defrosted to room tem-
perature, dried and fixed in aceton for 10 minutes. After
fixation, tissue sections were rinsed with phosphate-buf-
fered saline (PBS, pH 7.8).
Sections were incubated with mouse anti-human
monoclonal antibody directed against BDCA-1 (AD5-
8E7) (Miltenyi Biotec, Bergisch Gladbach, Germany) fol-
lowing incubation with normal goat serum (CLB,
Amsterdam, the Netherlands). Sections were then incu-
bated with biotinylated goat anti-mouse antibody (Bio-
genics, Klinipath, Duiven, the Netherlands). Next,
sections were incubated with streptavidin alkaline phos-
phatase (ss-AP, Biogenics, Klinipath, Duiven, the Neth-
erlands). Sections were then rinsed with PBS containing
TRIS buffer (0.2 mol/L, pH 8.5) and incubated with new
fuchsine (Chroma, Kongen, Germany) substrate (con-
taining levamisole to block endogenous alkaline phos-
phatase enzyme activity), counterstained with
hematoxylin and mounted in Vecta Mount (Vector, Bur-
lingame, CA, USA).
Aceton-fixed cryosections were stained with mouse
anti-human DC-SIGN ((clone DCN46), BD Biosciences,
Erembodegem, Belgium) following incubation with
blocking reagent (Roche 1096176, Basel, Switzerland).
Sections were then incubated with poly-alkaline phos-
phatase goat anti-mouse (Klinipath, Duiven, the Nether-
lands). Sections were incubated with new fuchsine
(Dako, Heverlee, Belgium) with levamisole during
7 minutes, counterstained with Mayer’s hematoxylin
(Sigma, Belgium), rinsed with distilled water and
mounted in Aquatex (Klinipath).
Immunohistochemical staining for langerin was car-
ried out on cryosections as described previously [22].
For immunohistochemical double staining, aceton
fixed cryosections were incubated with blocking reagent
(Ultra V Block : Klinipath: TA-125-UB), followed by the
first monoclonal antibody (anti human BDCA-1, (clone
AD5-8E7) (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) or anti human DC-SIGN (clone DCN46, BD
Biosciences, Erembodegem, Belgium) during 1 hour at
room temperature. Sections were then incubated with
poly-Alkaline phosphatase (DPVM 55AP, Klinipath,
Duiven, The Netherlands) stained with new fuchsin as
described above. After rinsing, streptavidin/biotin block-
ing was applied (SP-2002, Vector, Burlingame, CA) fol-
lowed by blocking reagent (Roche 1096176, Basel,
Switzerland). Sections were incubated overnight with
mouse anti-human CD207 (langerin, clone DCGM4,
Immunotech, Marseille, France) diluted in PBS. Sections
were rinsed with PBS and incubated with biotinylated
goat-anti-mouse IgG1 (Southern Biotech Birmingham,
USA). Sections were rinsed in PBS and incubated with
streptavidin-AP (Vector, Burlingame, CA). Finally, sec-
tions were stained with Vector Blue diluted in PBS
with 0.3% Triton (Sigma, Belgium) at pH 8.2 combined
with levamisole. After terminating the staining process
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rinsed with distilled water and covered with Aquatex as
described above.
3 μm thick paraffin embedded sections were cut on
poly-L-lysin coated slides. After dewaxing with Ultra
Clear (Klinipath, Duiven, The Netherlands) and rehydra-
tion, antigen retrieval was performed using preheated
Citrate buffer pH 6.0 (ScyTek Laboratories, Logan,
Utah, USA) 10% at 78°C. After blocking of endogenous
peroxidase activity with 3% hydrogen peroxide (Dako,
Heverlee, Belgium) and application of blocking reagent
(Roche 1096176, Basel, Switzerland) 1% in PBS with
0.3% Triton, sections were incubated with mouse anti-
human CD1a monoclonal antibody (M3571, Dako,
Heverlee, Belgium) followed by incubation with biotiny-
lated link antibody and application of streptavidin-HRP
(LSAB system K0679, DAKO, Heverlee, Belgium). Slides
were rinsed in PBS containing 0.3% Triton. Finally, dia-
minobenzidine substrate was added for 30 minutes, sec-
tions were rinsed in demineralised water, counterstained
with Mayer’s hematoxylin (Sigma, Belgium), dehydrated
and mounted in DPX (Klinipath, Duiven, The
Netherlands).
Immunohistochemical staining for for Activin-A was
also performed on paraffin-embedded sections, using
the same dewaxing and rehydration protocol as
described above. Antigen retrieval was performed using
EDTA-buffer. After blocking for endogenous peroxidase
activity and application of Fc block, slides were incu-
bated with anti-human Activin-A ((Clone E4) ABD Ser-
otec, Kidlington, United Kingdom) during 12 h at 4°C.
Next, sections were further stained as described in the
protocol for CD1a.
For each primary antibody used, appropriate isotype
control stainings were performed.
Image analysis
Images of tissue sections were recorded using a compu-
terized image analysis system (KS400, Zeiss, Oberko-
chen, Germany). Airways without cartilage that had a
perimeter of the basement membrane of less than 6000
μm were selected for analysis [7]. The area of epithelium
was defined by the region between the luminal border
and the basement membrane, the lamina propria as the
region between the basement membrane and the outer
edge of the smooth muscle and the adventitia as the
region between the outer border of the smooth muscle
and the outer border of the small airway. The total air-
way wall was defined as the sum of these 3 regions. The
number of positive cells in the epithelium was counted
and the results were normalized to the area of the
epithelium and to the length of the basement mem-
brane. For the lamina propria, adventitia and total air-
w a yw a l l ,t h en u m b e ro fp o s i t ive cells were normalized
to the surface of the respective area. Cells were regarded
positive when showing DC morphology and contained a
nucleus. The observer (GRVP) was blinded for clinical
data. A random sample of 45 slides was analysed by a
second blinded observer (KD), showing good interobser-
ver agreement (paired T test p = 0.18) and a good cor-
relation between the two observers (p < 0.001, Pearson
correlation coefficient 0.85).
mRNA expression study
Total lung RNA was extracted with the RNeasy Mini Kit
(Qiagen, Hilden, Germany). RNA quality was checked on
a bioanalyser and samples with an RNA-integrity number
(RIN) below 5.5 were excluded from the analysis. Subse-
quently cDNA was obtained by reverse transcription of
RNA with the Transcriptor First Strand cDNA synthesis
kit (Roche, Basel, Switzerland) following manufacturer’s
instructions and using a 2:1 ratio of hexa:oligodT primers.
Expression of target genes Activin A (Inhibin beta A),
RANKL, Notch Ligand Delta-1 and IL-15 and reference
genes GAPDH (glyceraldehyde-3-phosphate dehydrogen-
ase), HPRT1 (hypoxanthine phosphoribosyltransferase 1)
and PPIA (peptidylprolyl isomerase 1) mRNA was ana-
lysed with the TaqMan Gene Expression Assays (Applied
Biosystems, Forster City, CA, USA). Real-time PCR reac-
tions were performed in duplicate using diluted cDNA
template and the LightCycler480 Probes Master (Roche,
Basel, Switzerland). A standard curve derived from the
serial dilutions of a mixture of all samples was included on
each plate. Amplifications were performed on a LightCy-
cler480 detection system (Roche, Basel Switzerland) with
the following cycling conditions: 10 min incubation at
95°C and 50 cycles of 95°C for 10 sec and 60°C for 15 sec.
Data were processed using the standard curve based
method. Expression of target genes was corrected by a
normalisation factor that was calculated based on the
expression of three reference genes (GAPDH, HPRT1,
PPIA), using the geNorm applet according to the guide-
lines and theoretical framework previously described
http://medgen.ugent.be/~jvdesomp/genorm/[33] In
44 patients, both total lung RNA and langerin stained
cryosections were available.
Statistical analysis
Statistical analysis was carried out in SPSS 16.0 (SPSS
inc. Chicago, IL, USA). When evaluating differences in
continuous variables between multiple independent
groups, the Kruskal-Wallis test was used. Where values
of probability were <0.05, selected pairs of groups were
investigated by the Mann-Whitney U test. Correlation
coefficients were calculated using Spearman’sr a n k
method. Linear regression analysis was performed on
log-transformed data, using the enter method. P values
< 0.05 were considered significant.
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Characterization of pulmonary Langerhans-type and
interstitial-type DC
Figure 1 shows the flowcytometric identification of lan-
gerin (CD207)+ LDC and DC-SIGN (CD209)+ intDC in
single cell suspensions of digested human lung tissue,
using the previously described low autofluorescent, CD3
negative, CD19 negative gating strategy [13]. The clinical
characteristics of the study population and the propor-
tion of each DC marker within the HLA-DR positive
population are shown in table 1.
LDC and intDC were consistently identified as two
separate populations (figure 1A). A large proportion of
LDC expressed the myeloid DC marker BDCA-1 (figure
1B), but in multiple independent experiments, a small
population of BDCA-1 negative LDC was consistently
found. The majority of CD1a+ DC expressed BDCA-1
(figure 1C), but only a minor subset of CD1a+ DC
expressed langerin. Moreover, the majority of LDC was
CD1a negative (figure 1D).
Immunohistochemical double staining on cryosec-
tions of lung resection specimens confirmed the segre-
gation of LDC and intDC, the former mainly present
in the epithelium, the latter in the lamina propria and
the adventitia (figure 2A). Double staining for langerin
and BDCA-1 confirms the presence of a double posi-
tive and the respective single positive populations
(figure s2B).
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Figure 1 Flowcytometric identification of langerin+ Langerhans type dendritic cells and DC-SIGN + interstitial type dendritic cells on
single cell suspensions of digested human lung tissue, using the low autofluorescent, CD3 and CD19 negative gating strategy. (A):
Langerin+ and DC-SIGN+ dendritic cells are two separate dendritic cell populations. (B-D): interrelationship of langerin, CD1a and BDCA-1 on low
autofluorescent, CD3 and CD19 negative dendritic cells. (representative of 6 independent experiments).
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file compared to LDCs. Representative histograms
comparing the expression profile on LDC and intDC
are shown in figure 3A and 3B. In addition, quantita-
tive data on these expression profiles are shown in
Table 2. IntDC did not express BDCA-1 and CD1a.
The expression of BDCA-4 tended to be higher in
intDC than in LDC. Another blood dendritic cell anti-
gen (BDCA-3) was expressed on both subsets. IntDC
expressed CD14 and a variable degree of CD163,
showing their close relationship with monocytes and
macrophages. Nearly all LDC express HLA-DR (97%),
whereas only a proportion (40%) of intDCs expressed
this marker.
Both intDC and LDC expressed BDCA-3 on flowcyto-
metric analysis, which is the previously described mar-
ker for the pulmonary myeloid DC type 2 subset [13].
However, as shown in figure 3, LDC and intDC both
expressed BDCA-3 at an intermediate level. We consis-
tently found in all experiments a low autofluorescent,
CD3 negative, CD19 negative, HLA-DR positive popula-
tion that expressed BDCA-3 at a high level (Figure 4)
This BDCA-3 high cell population did not express
BDCA-1, DC-SIGN, langerin or BDCA-2 (a pDC mar-
ker), suggesting that this is also a separate myeloid DC
population.
Distribution and quantification of dendritic cells in small
airways
Clinical characteristics of the study population
Table 3 shows the clinical characteristics of the study
population consisting of 85 patients (11 never-smokers,
14 current smokers without COPD, 14 ex-smokers with-
out COPD and 46 COPD patients).
DC-SIGN positive interstitial-type DC
Figure 5A-C shows representative cryosections of DC-
SIGN positive DC in small airways. These cells were
mainly located in the lamina propria and adventitia.
There were no significant differences in the number of
DC-SIGN positive DC between the study groups in the
total airway wall (figure 6A), the epithelium, lamina pro-
pria and adventitia (figure 7:A-C). No significant corre-
lation with FEV1 was found (data not shown).
Langerin positive Langerhans-type DC
Representative cryosections showing langerin+ DC are
displayed in figure 5 D-F. Langerin+ DCs were mainly
found in the epithelium and to a lesser extent in the
lamina propria and the adventitia. In the total airway
wall, the number of langerin+ DC was significantly
higher in all COPD groups compared to ex-smokers
without COPD (figure 6B). This increase was due to a
significant accumulation of these cells in the epithelium
and adventitia, with additional higher numbers of
Figure 2 Immunohistochemical double staining for myeloid
dendritic cell markers. (A): Immunohistochemical double staining
for DC-SIGN+ interstitial type dendritic cells (red) and langerin+
Langerhans type dendritic cells (Blue) in small airway of human lung.
Langerin+ cells are mainly present in the epithelium, whereas DC-
SIGN+ cells are localized in the lamina propria and adventitia. There
are no double positive cells, confirming the segregation of these
two cell types in human lung. (B): Immunohistochemical double
staining for BDCA-1+ myeloid dendritic cells and langerin+
Langerhans type dendritic cells in small airway of human lung. A
single positive BDCA-1 + cell (red), a langerin positive cell (blue) and
a double positive cell (purple, marked with an arrow) are present.
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COPD GOLD stage III&IV (p = 0.045). (figure 7D-F).
In current smokers without COPD, the number of
langerin+ DCs tended to be higher in the total airway
wall (p = 0.060) and in the epithelium (p = 0.062) com-
pared to ex-smokers without COPD. When the number
of cells in the epithelium was expressed per unit of
length of the basement membrane, significantly higher
numbers were observed in the epithelium of current
smokers compared to ex-smokers without COPD (p =
0.012) (data not shown). In addition, the number of lan-
gerin+ DC was significantly higher in the lamina propria
and adventitia of current smokers without COPD com-
p a r e dt on e v e rs m o k e r s( p=0 . 0 0 8a n dp=0 . 0 3 3 ) .
Table 1 Characteristics of the Study Population (flowcytometry) (n = 6)
subject 1 2 3 4 5 6
gender MM F M M M
Age (years) 60 76 63 67 77 69
Smoking history (packyear) 0 0 40 40 35 50
Current or ex smoker NA NA current current ex ex
FEV1 (%pred) 77.0 111.0 94.0 97.0 74 75.0
FEV1(L) 2.4 3.0 1.8 2.9 1.9 1.9
FEV1/FVC (%) 70 76 68 68 64 58
LABA (Yes/No) No No No No No No
Inhaled CS (Yes/No) No No No No No No
Systemic CS (Yes/No) No No No No No No
Study group Never Smoker Never Smoker COPD* COPD* COPD* COPD*
% Langerin + cells 2.0 5.4 1.7 1.0 0.9 16.5
% DC-SIGN + cells 2.0 14.1 0.8 0.7 1.0 2.9
% BDCA-1 + cells 4.2 14.2 2.5 2.0 2.5 13.4
% BDCA-3 high + cells 20.0 3.7 6.0 7.9 2.5 4.0
% BDCA-1+ cells on LDC 73.5 88.0 80.8 75.0 64.1 14.2
Data are provided per subject. CS: corticosteroids; FEV1: forced expiratory volume in one second postbronchodilator; FVC: forced vital capacity; LABA : long acting
b 2 agonist; M: Male, F: Female; (*): spirometry-based diagnosis of COPD according to GOLD criteria.
Flowcytometric data on single cell suspensions are presented as % of HLA-DR positive cells within the low autofluorescent, CD3 negative, CD19 negative cell
population. LDC: langerhans-type dendritic cell.
Figure 3 Characterization of langerin positive and DC-SIGN positive dendritic cels. Expression of BDCA-1, CD1a, BDCA-3, BDCA-4, CD14,
CD163 and HLA-DR are represented by the blue histograms. Red histograms represent the matched isotype control staining. Results are
representative of 6 independent experiments.
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smokers and ex-smokers without COPD in any layer of
the small airway. Importantly, there were also no differ-
ences between current and ex-smoking COPD GOLD
stage I/II. There were significant negative correlations
between the forced expiratory volume in 1 second
(FEV1) % predicted and the number of langerin positive
cells in the epithelium (correlation coefficient rs -0.39;
p < 0.001), lamina propria (rs -0.30, p = 0.006), adventi-
tia (rs -0.38; p < 0.001) and total airway wall (rs -0.36;
p = 0.001). This association between FEV1 (% predicted)
and the number of langerin+ DC in the small airways
remained significant, even after adjustment for possible
confounders (age, gender, amount of packyears smoked,
current versus non-current smoker, treatment with
inhaled corticosteroids and treatment with oral corticos-
teroids) by linear regression analysis (Table 4).
BDCA-1 positive DC
Representative cryosections are shown in figure 5 G-I.
BDCA-1+ DC were mainly found in the epithelium and
the lamina propria. The number of BDCA-1+ DC was
significantly lower in the total airway wall of all COPD
groups compared to never smokers (p = 0.042 for COPD
GOLD I&II current smokers, p = 0.032 for COPD GOLD
I&II ex-smokers and p < 0.001 for COPD GOLD III&IV
ex-smokers) (figure 6C). Importantly, the number of
these DC in the total airway wall was lower in COPD
GOLD stage III/IV compared to the milder stages of the
disease (p = 0.003 versus COPD GOLD I&II current
smokers and p = 0.058 vs COPD GOLD I-II ex-smokers).
There were no significant differences between current
and ex-smoking COPD GOLD I&II and between current
and ex-smokers without airway obstruction. When
focusing on the lamina propria and adventitia (fig 7H-I),
the number of BDCA-1 positive DC was significantly
lower in current smokers without airway obstruction
compared to never smokers (p = 0.044 and p = 0.032,
respectively) There was a significant positive correlation
between the FEV1 (% predicted) and the number of
BDCA-1+ DC in the epithelium (rs 0.39; p < 0.001),
lamina propria (rs 0.35; p = 0.001), adventitia (rs 0.36 ;
p = 0.001) and total airway wall (rs 0.40; p < 0.001). The
association between FEV1 (% pred) and the number of
BDCA-1 positive DC in the small airways was investi-
gated by linear regression analysis (Table 5). This
revealed that the decrease in BDCA-1 positive DC in
the lamina propria is predominantly associated with the
use of inhaled corticosteroids, which are mostly pre-
scribed in the COPD patients with the lowest FEV1. In
contrast, an independent association of FEV1 and
BDCA-1+ DC was still observed in the epithelium and
the adventitia. Gender did not influence the association
between FEV1 and the number of BDCA-1 positive DC
(data not shown).
Importantly, there was a trend towards an inverse cor-
relation between the number of langerin+ DC in the
total airway wall and the number of their known
BDCA-1+ precursors: (rs -0.21, p = 0.056).
CD1a positive DC
Representative paraffin embedded sections showing
CD1a+ DC are presented in figure 5J-L. CD1a + DC
were mainly present in the adventitia and the lamina
propria of the small airways. There were no significant
changes in the number of CD1a+ DC in either the
total airway wall (fig 6D), the epithelium, the lamina
propria or the adventitia between the different groups
(figure 7:J-K). No significant correlations with the
post-bronchodilator FEV1 (% predicted) were found
(data not shown).
Factors involved in Langerhans-type DC differentiation
and survival
The characteristics of the study population are shown in
Table 6.
The results of the mRNA expression of the different
factors (activin-A, RANK-Ligand, notch ligand delta-1
Table 2 Expression of Surface Markers on interstitial-type and langerhans-type DC (flowcytometric analysis of
lung digest)
Surface
marker
% positive cells Mean Fluorescence Intensity
intDC LDC p intDC LDC p
BDCA-1 6.3 [1.7-9.6] 72.6 [42.1-81.7] ** 9.6 [3.1-16.5] 60.2 [48.3-140.0] **
CD1a 3.1 [0.3-5.2] 54.1 [23.0-73.8] * 13.4 [4.4-30.3] 112.4 [38.2-203.0] *
BDCA-3 54.3 [13.5-98.1] 56.2 [3.2-97.3] ns 54.0 [44.3-168.0] 35.4 [21.2-156.0] ns
BDCA-4 15.0 [1.9-57.1] 4.6 [0.0-15.0] ns 33.0 [8.6-89.6] 14.5 [8.6-38.5] ns
CD163 4.5 [3.0-46.2] 4.3 [0.6-26.8] ns 27.1 [11.9-186.0] 20.0 [3.7-127.0] ns
CD14 57.2 [20.4-81.5] 10.2 [2.5-23.1] * 56.3 [11.5-207.0] 12.6 [3.6-87.8] ns
HLA-DR 56.3 [21.4-98.5] 88.7 [73.1-98.7] ns 132.0 [31.7-2399] 544.0 [484.0-1629.0] ns
Data are expressed as median [range]
intDC: interstitial-type dendritic cell; LDC: langerhans-type dendritic cell
p value compairing two groups (Mann-Whitney-U test): *: p < 0.05; **: p < 0.01; ns: not significant
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Page 8 of 21and IL-15) involved in LDC differentiation and survival
are shown in figure 8A-D. For all the investigated fac-
tors, no significant differences in mRNA expression
between groups were observed. However, there was a
trend towards higher expression of activin-A in current
smokers with COPD compared to never smokers and
ex-smokers without COPD (p = 0.07 and p = 0.08
respectively). Moreover, there was a significant positive
correlation between the expression of activin-A and the
number of LDCs in the small airway (epithelium rs 0.33;
p = 0.028, lamina propria rs 0.46 p = 0.002, adventitia rs
0.49; p = 0.001 and total airway wall rs 0.36 p = 0.016)
(figure 8E). There were no significant correlations
between the numbers of LDC and the expression of
RANK-ligand, Notch ligand delta-1 or IL-15. Immuno-
histochemical staining of Activin-A confirms expression
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Figure 4 Interrelationship between BDCA-3 expression and (A) langerin, (B) DC-SIGN, (C) BDCA-1 and (D) BDCA-2 on low
autofluorescent, CD3 negative, CD19 negative, HLA-DR positive cells.
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Page 9 of 21of this factor in the small airway at protein level, and
shows its localization in the epithelium, the smooth
muscle layer and in the mononuclear cellular infiltrate
(figure 9).
Discussion
This is the first study characterizing langerin+ Langer-
hans-type and DC-SIGN+ interstitial type DC as two
separate populations in single cell suspensions of
digested human lung tissue. Moreover, the extensive
immunohistochemical study showed a selective accumu-
lation of the LDC subset in small airways of current
smokers and COPD patients, which correlated with its
differentiation factor Activin-A. These data suggest a
role for the LDC subset in the initiation of airway
inflammation in susceptible smokers and perpetuation
of this destructive process in COPD, even after smoking
cessation.
Flowcytometric characterization of the segregation of
LDC and intDC was confirmed in small airways using
immunohistochemical double staining, which also
showed that LDC are mainly present in the epithelium,
whereas intDC are mainly localized in the lamina pro-
pria and adventitia. These findings are parallel to the
known distribution of these two DC subsets in human
skin [11].
A schematic overview of the interrelationship between
different pulmonary myeloid DC markers is provided in
figure 10. Pulmonary LDC are closely related to the pre-
viously described pulmonary myeloid DC type 1
(mDC1) defined by BDCA-1. Indeed, in vitro studies on
monocyte derived DC have shown that BDCA-1 and
CD1a double positive DCs are direct precursors of these
LDC [20]. CD1a, present on a subset of pulmonary
BDCA-1+ DCs, is also present on a subgroup of LDC,
but not all LDC co-express CD1a, suggesting that CD1a
is not a good surrogate marker for pulmonary LDC.
Moreover, this finding is supported by the distribution
of CD1a in the small airways of human lungs which is
completely different from langerin and BDCA-1 as
CD1a positive cells are mainly present in the lamina
propria and the adventitia. This difference in distribu-
tion of BDCA-1 and CD1a + DCs was also observed by
Masten et al, showing higher quantification of CD1a
positive DCs in the subepithelial regions compared to
the epithelium [14].
In contrast, pulmonary intDC do not express BDCA-1
and CD1a, indicating that these DC are in a separate
differentiation axis, more closely related to monocytes
and macrophages, as hypothesized previously [12].
Although BDCA-3 can be expressed at an intermedi-
ate level on both the mDC1 related LDC and on intDC,
BDCA-3 high expression is confined to a separate popu-
lation of DC, that does not express BDCA-1, langerin,
D C - S I G No rt h ep D Cm a r k e rB D C A - 2 .T h i ss e p a r a t e
BDCA-3 high DC population could be regarded as a
more accurate definition of the previously described
myeloid DC type 2 (mDC2) [13]. It is unclear how this
pulmonary mDC2 population is exactly related to the
other DC subsets in terms of differentiation pathways,
as there are currently no in vitro data available on this
issue. Since we demonstrated that mDC2 also partially
Table 3 Characteristics of the Study Population (immunohistochemical study) (n = 85)
Never
Smokers
Current
Smokers
without COPD
Ex-Smokers
without
COPD
COPD I-II
Current
Smokers
COPD I-II
Ex-Smokers
COPD III-IV
Ex-Smokers
n 11 14 14 23 13 10
Sex ratio (M/F) 3/8 9/5 12/2 22/1 13/0 4/6
Age (years) 57.6 (11.5) 55.6 (11.0) 63.7 (7.4)
† 63.0 (9.0)
† 69.5 (6.9)*
†‡Δ 57.3 (5.0)
‡Δ∞
Smoking history (packyear) N.A. 31.4 (12.0) 39.1 (35.6) 46.5 (21.1)
† 42.5 (23.2) 44.5 (41.8)
Years quit smoking N.A. 0.2 (0.2) 18.0 (10.3)
† 0.1 (0.2)
†‡ 9.9 (7.3)
†‡Δ 5.1 (2.5)
†‡Δ
FEV1(%pred) 102.4 (13.0) 102.3 (13.7) 102.6 (19.1) 74.2 (13.2)*
†‡ 83.6 (11.0)*
†‡ 27.0 (9.9)*
†‡Δ∞
FEV1(L) 2.8 (0.9) 3.1 (0.4) 3.2 (1.0) 2.4 (0.5)
†‡ 2.5 (0.4)
† 0.7 (0.3)*
†‡Δ∞
FEV1/FVC (%) 77.0 (7.1) 77.9 (4.7) 76.2 (5.8) 57.3 (8.0)*
†‡ 60.3 (5.3)*
†‡ 37.7 (10.9)*
†‡Δ∞
LABA (Y/N) 0/11 0/14 0/14 6/17 3/10 10/0
Inhaled corticosteroids (Y/N) 0/11 0/14 0/14 5/18 2/11 10/0
Inhaled corticosteroid dose (μg BDP/24 h) 0 0 0 369.6 (771.9) 307.7 (751.1) 1660 (550.2)*
†‡Δ∞
Systemic corticosteroids (Y/N) 0/11 0/14 1/13 1/22 0/13 7/3
Systemic corticosteroid dose (mg prednisolon/24 h) 0 0 0.4 (1.6) 0.4 (2.1) 0 5.5 (4.4)*
†‡Δ∞
Data are expressed as mean (standard deviation);
* p < 0.05 vs never smoker; † p < 0.05 versus current smoker without COPD; ‡ p < 0.05 versus ex-smoker without COPD; Δ p < 0.05 versus COPDI-II current
smoker; ∞ p < 0.05 versus COPD I-II ex-smoker.
FEV1: forced expiratory volume in one second;
FVC: forced vital capacity;
LABA : long acting b 2 agonist; BDP: beclomethasone diproprionate.
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Page 10 of 21Figure 5 Immunohistochemical staining for dendritic cell markers DC-SIGN (CD209) (A), (B), (C); langerin (CD207) (D), (E), (F); BDCA-1
(CD1c) (G), (H), (I); and CD1a (J), (K), (L) in sections of a small airway of a current smoker without COPD and an ex-smoking COPD
patient GOLD stage I. Original magnification: 100×. Pictures in the right column show a detail:(C), (F) and (I) are detailed pictures from the first
column. (L) is a detail from the second column (K).
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Page 11 of 21Figure 6 Box and whisker plots: Quantification of DC-SIGN positive (interstitial-type) dendritic cells (A), Langerin positive (Langerhans-
type) dendritic cells (B), BDCA-1 positive myeloid dendritic cells (C) and CD1a positive dendritic cells (D) in small airways of never
smokers, current smokers without COPD, ex-smokers without COPD, current smoking COPD patients GOLD I-II, ex-smoking COPD
patients GOLD I-II and ex-smoking COPD patients GOLD stage III&IV. Data are presented as number of dendritic cells/area of total airway
wall (cells/mm
2). Significant differences between 2 groups (p values <0.05), generated by the Mann-Whitney-U test after analysis of variance are
marked with a full line, p values between 0.05 and 0.08 are marked by a dashed line.
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Page 12 of 21Figure 7 Box-and Whisker plots: Quantification of myeloid dendritic cells in small airways of never-smokers (n = 11), current smokers
without COPD (n = 14), ex-smokers without COPD (n = 14), current smoking COPD patients GOLD stage I&II (n = 23), ex-smoking
COPD patients GOLD stage I&II (n = 13) and ex-smoking COPD patients GOLD stage III&IV (n = 10). A-C: DC-SIGN positive intersititial type
dendritic cells. D-F: langerin positive Langerhans-type dendritic cells, G-I: BDCA-1 positive dendritic cells and J-L: CD1a positive dendritic cells.
Data are presented as number of dendritic cells/area of epithelium, lamina propria or adventitia (cells/mm
2). Significant differences between two
groups (p values < 0.05), generated by Mann-Whitney-U test after analysis of variance are marked with a full line, p values between 0.05 and
0.08 are marked with a dashed line.
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Page 13 of 21Table 4 Linear Regression Analysis (Quantification Langerin+ DC in small airways)
DC surface marker R
2 Predictor Variable b p
Langerin+ DC in Total Airway Wall 0.23 FEV1(% pred) -0.436 0.002
Age -0.088 0.441
Gender 0.186 0.105
Packyear 0.065 0.592
Smoking status 0.011 0.920
Inhaled CS 0.006 0.968
Oral CS 0.047 0.705
Langerin+ DC in Epithelium 0.20 FEV1(% pred) -0.398 0.006
Age -0.049 0.674
Gender 0.130 0.264
Packyear 0.031 0.805
Smoking status 0.090 0.427
Inhaled CS 0.019 0.898
Oral CS 0.046 0.715
Langerin+ DC in Lamina Propria 0.16 FEV1(% pred) -0.350 0.018
Age -0.076 0.525
Gender 0.160 0.179
Packyear 0.111 0.381
Smoking status 0.078 0.503
Inhaled CS -0.093 0.542
Oral CS 0.125 0.336
Langerin+ DC in Adventitia 0.40 FEV1(% pred) -0.434 0.001
Age 0.045 0.673
Gender 0.217 0.039
Packyear -0.028 0.799
Smoking status 0.115 0.271
Inhaled CS 0.187 0.176
Oral CS 0.072 0.542
Abbreviations: DC: dendritic cell; FEV1(% pred): forced expiratory volume in one second (% predicted); CS: corticosteroids.
b:standardized coefficient. Smoking status: current versus non-current smoker
Significant p values are marked in bold.
Table 5 Linear Regression Analysis (Quantification BDCA-1+ DC in small airways)
DC surface marker R
2 Predictor Variable b p
BDCA-1+ DC in Total Airway Wall 0.08 FEV1(% pred) -0.172 0.468
Inhaled CS 0.045 0.130
Oral CS -0.172 0.826
BDCA-1+ DC in Epithelium 0.12 FEV1(% pred) 0.333 0.034
Inhaled CS 0.064 0.710
Oral CS -0.110 0.420
BDCA-1+ DC in Lamina Propria 0.23 FEV1(% pred) 0.003 0.981
Inhaled CS -0.520 0.002
Oral CS 0.100 0.418
BDCA-1+ DC in Adventitia 0.12 FEV1(% pred) 0.404 0.011
Inhaled CS 0.062 0.724
Oral CS 0.043 0.747
Abbreviations: DC: dendritic cell; FEV1(% pred): forced expiratory volume in one second (% predicted); CS: corticosteroids.
b:standardized coefficient.
Significant p values are marked in bold.
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Page 14 of 21express CD14, we suggest that mDC2 are a fourth mod-
ality of differentiating mon o c y t e s( a p a r tf r o mm a c r o -
phages, interstitial type DC and the mDC1-LDC axis).
A recent study by Tsoumakidou et al addressed the
issue of different myeloid DC subsets in human lung
digests by immunocytochemical staining of in vitro
adhered pulmonary cells [34]. The target cell population
o ft h a ts t u d yw a sm a i n l yam a t u r eC D 8 3 +C D 1 a +p o p u -
lation. They also found that langerin, BDCA-1 and CD1a
are not necessarily co-expressed. In addition, a substan-
tial percentage of these cells also expressed BDCA-3.
These results are generally in line with our findings.
Unexpectedly, a high percentage of the cells in the study
by Tsoumakidou et al also expressed the plasmacytoid
DC (pDC) marker BDCA-2. This finding is in sharp con-
trast to the results of other research groups, including
ours, showing that pDC are truly separated from myeloid
D C .O u rs t u d yh a st h ea d v a n t a g eo ft h er e a l - t i m es i m u l -
taneous analysis of the different DC surface markers by
flowcytometry, which generates more accurate results
than the quantification of sequential immunocytochem-
ical single stainings of adhered DC that could be pheno-
typically altered by the incubation in vitro.
Importantly, the relative proportions of different DC
subsets differ, depending on the technique used for
quantification. As lung digests contain cells from the
different compartments of the lung specimen (airways,
alveoli, lymphoid follicles, blood vessels and blood), the
proportion of DC markers which are both expressed on
circulating blood DC and tissue resident DC (such as
BDCA-1) is generally higher compared to the tissue
resident DC markers langerin and DC-SIGN in
flowcytometric experiments. In contrast, when the focus
is strictly on the small airway (in the immunohisto-
chemical analysis), the tissue resident DC markers out-
number the BDCA-1 positive DC.
The immunohistochemical study of the different mye-
loid DC subsets in the small airways revealed a shift of
the myeloid DC population towards a Langerhans phe-
notype with higher numbers of LDC in COPD patients
compared to never smokers and ex-smokers without
COPD. Moreover, the number of LDC further increased
with the severity of the disease, confirming the results of
our previous observations [22]. In accordance with pre-
vious studies in BAL [27,28], the number of LDC was
higher in current smokers without COPD compared to
never smokers or ex-smokers. In contrast, the number
of LDC was not different between current smoking and
ex-smoking COPD patients, supporting the concept of
ongoing inflammation in COPD, despite smoking
cessation.
Quantification of BDCA-1 positive DC revealed a com-
pletely different result with a significantly lower number
of these DC in COPD patients compared to never smo-
kers, especially in the lamina propria. Moreover, the
number of BDCA-1+ DC further decreased with the
severity of the disease. In line with the results of Soler et
al [26], we found no differences in the number of epithe-
lial BDCA-1+ cells between current smokers and ex-or
never smokers. In addition, there was no effect of current
smoking on the numbers of BDCA-1 positive DC in
COPD patients. This marked divergence between the
numbers of LDC and BDCA-1 positive DC could be
explained by an alteration in the DC differentiation
Table 6 Characteristics of the Study Population (mRNA expression study) (n = 55)
Never Smokers Current Smokers
without COPD
Ex-Smokers
without COPD
COPD
Current Smokers
COPD
Ex-Smokers
n 10 7 10 17 11
Sex ratio (M/F) 3/7 3/4 8/2 14/3 11/0
Age (years) 59.5 (11.2) 53.1 (13.4) 63.6 (7.7) 63.9 (9.5) 69.3 (7.7)
Smoking history (packyear) 0 34.8 (12) * 37.5 (20.6) * 41.2 (16.9) † 56.1 (24.1) *
Years quit smoking N.A. 0.0 9.0 (10.7) † 0.0 ‡ 5.8 (6.0)†Δ
FEV1 (%pred) 97.3 (13) 101.8 (16.7) 112.2 (10.1) 68.3 (13.6)*†‡ 68.8 (14.6)*†‡
FEV1 (L) 2.8 (0.7) 2.9 (0.4) 3.4 (0.7) 2.3 (0.6)‡ 2.1 (0.5)*†‡
FEV1/FVC (%) 77.2 (8.1) 77.2 (4.9) 77.2 (6.1) 56.1 (7.0)*†‡ 55.6 (9.2)*†‡
LABA (Y/N) 0/10 0/7 0/10 6/11 5/6
Inhaled corticosteroids (Y/N) 0 0 0 6/11 5/6
Inhaled corticosteroid dose (μg BDP/24 h) 0 0 0 538.5 (877.1)*†‡ 663.6 (897.0)*†‡
Systemic corticosteroids (Y/N) 0/10 0/7 0/10 3/14 1/10
Systemic corticosteroid dose (mg prednisolon/24 h) 0 0 0 3.1 (10.0) 0.9 (3.0)
Data are expressed as mean (standard deviation);
* p < 0.05 vs never smoker; † p < 0.05 versus current smoker without COPD; ‡ p < 0.05 versus ex-smoker without COPD; Δ p < 0.05 versus COPD current smoker.
FEV1: forced expiratory volume in one second;
FVC: forced vital capacity;
LABA : long acting b 2 agonist; BDP: beclomethasone diproprionate.
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Page 15 of 21Figure 8 mRNA expression in total lung of factors capable of inducing differentiation of monocytes towards Langerhans cells in never
smokers, current smokers without COPD, ex-smokers without COPD, current smoking COPD patients and ex-smoking COPD patients.
(A) expression of Activin-A, (B) RANK-ligand, (C) notch-ligand delta-1 and (D) interleukin 15. mRNA expression is shown as the ratio of the
number of transcripts of the gene of interest to the number of transcripts for the housekeeping genes. (E) Correlation of the mRNA expression
levels of Activin-A, with the number of langerin positive cells in the total airway wall of the small airway. Correlation coefficient and p value are
shown.
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Page 16 of 21Figure 9 Immunohistochemical staining for Activin-A in small airway of human lung (A). Detail of the airway epithelium (B). Isotype
control staining is presented in (C) and (D). Activin-A is strongly expressed in the airway epithelium and smooth muscle layer. The mononuclear
cell infiltrate also expresses Activin-A. A mild expression is also observed the connective tissue of the lamina propria and adventitia.
Figure 10 Proposed schematic representation of the interrelationship of pulmonary myeloid dendritic cell subsets assessed by
flowcytometry. Pulmonary langerin positive Langerhans-type dendritic cells (LDC) are partially express CD1a and are closely related to BDCA-1
positive dendritic cells. These cells are separated from the interstitial type dendritic cells (intDC), which are identified by DC-SIGN and the
myeloid dendritic cell type 2 (mDC2), identified by BDCA-3 high expression. Dimensions of the Venn-diagrams are not proportional to the
absolute size of the different pulmonary DC subsets.
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Page 17 of 21process. Indeed, adding TNF-alpha - a factor that is cap-
able of driving the differentiation towards LDC - to a
monocyte derived DC culture system, induces a lower
expression of BDCA-1, compared to IL-4 generated DCs
[35]. The fact that in our study the number of LDC
tended to be inversely correlated with the number of
BDCA-1+ DC in the small airways further supports this
concept of an enhanced DC differentiation process
towards a LDC phenotype in patients with COPD.
Finally, this concept of enhanced LDC differentiation is
compatible with the flowcytometric results on lung
d i g e s t sa ss h o w ni nt a b l e1 .T h i sr e v e a l e dt h a tt h ep e r -
centage of LDC expressing BDCA-1 tended to be lower
in patients with moderate COPD (subject 3 and 6) com-
pared to never smokers, suggesting that in COPD,
BDCA-1 expression on LDC is reduced.
Quantification of CD1a, a marker present on both the
BDCA-1+ precursors of LDC and on a subset of LDC,
showed no differences between groups, indicating that
smoking or COPD does not alter the number of CD1a
positive DC in the small airways. These data confirm
and extend the data of Soler et al in bronchiolar epithe-
lium of smokers and non-smokers [26], and the pre-
viously published studies investigating the number of
CD1a positive DC in bronchial biopsies and small air-
ways of COPD patients [24,25]. These findings are in
contrast with the clear accumulation of CD1a positive
DCs in airways of asthmatics and of patients with dif-
fuse panbronchiolitis [36,37].
To our knowledge, this is the first study evaluating the
number of IntDC in small airways of smokers and
COPD patients. Importantly, our study showed no sig-
nificant differences in numbers of intDC in small air-
ways between groups.
Taken together, these data suggest an alteration of the
differentiation process of myeloid DC in small airways
of COPD patients resulting in a selective accumulation
of the LDC subset. The predominant accumulation of
LDC in COPD patients is an important finding, as LDC
are known to be potent activators of T helper1 cells and
cytotoxic T cell responses, both involved in COPD
pathogenesis [38]. Freeman et al recently showed that
the production of CD8+ T cell attracting chemokines
CCL-3 and CXCL-9 by CD1a positive lung DC (which
are closely related to LDC) increases with COPD sever-
ity [39]. Moreover, recent publications also highlight the
importance of LDC cells in activating Th17 cells [40], a
T cell subset that could contribute to the adaptive
immune response in COPD. In addition, LDC have dif-
ferent Toll-Like receptor expression compared to non-
LDC, making them less capable to pick up certain
microbial danger signals [41-43]. This could impair anti-
microbial defence, leading to low grade infections that
contribute to the destructive inflammation in COPD.
This functional evidence on LDC is derived from skin
DC or in vitro generated LDC. Further investigations to
elucidate the functional differences between pulmonary
Langerhans-type and non-Langerhans-type DC are war-
ranted in order to better understand the role of the dif-
ferent DC subsets in the initiation and perpetuation of
inflammation in COPD.
Multiple factors such as chemokines and cytokines
expressed by the airway epithelium, stromal cells and
inflammatory cells under the influence of cigarette
smoke and microbial stimuli can modulate the influx of
DC precursors, their differentiation towards a certain
phenotype and their capability to mature. It is also pos-
sible that in vivo, cigarette smoke could directly modu-
late certain DC functions. Previously, we reported an
activation of the CCL-20/CCR6 axis in COPD which
contributes to the influx of CCR6 expressing myeloid
DC [22]. Monocytes and circulating myeloid blood DC
are known precursors of LDC [19]. In vitro, the combi-
nation of Transforming Growth Factor beta (TGFb)a n d
Tumor Necrosis Factor alpha (TNFa) is crucial to
induce a langerin expression in monocyte derived DC
[18]. TGFb and TNFa, both increased in the lungs of
COPD patients [44,45], could therefore contribute to
the enhanced differentiation towards LDC (figure 11).
Recently, other factors capable of inducing LDC differ-
entiation and survival such as activin-A, notch ligand
delta-1, RANK-ligand and IL-15 were identified in vitro
and in the human skin. This study identifies pulmonary
expressed activin-A as the differentiation factor correlat-
ing with the accumulation of LDCs in the small airways,
highlighting its importance especially in current smo-
kers. In addition, we describe for the first time the
expression of activin-A in the small airways of human
lungs, especially in the area that contains the highest
concentration of langerin positive cells: the airway
epithelium. Activin-A is a TGFb superfamily member
known for its activity on growth and differentiation of
various cell types during organogenesis, and for its role
in wound healing and inflammation [29]. Apart from
inducing DC differentiation, activin-A is known to
attenuate the pro-inflammatory response of DC in the
context of stimulation with CD40 ligand, but not in the
context of Toll-Like Receptor 4 stimulation [46]. More-
over, activin-A is also involved in promoting the chemo-
taxis of immature myeloid DC [47].
There are several factors that strengthen this study.
First of all, this study is, to our knowledge, the largest
study (85 patients) addressing the quantification of mye-
loid DC in human lungs, using different markers and
taking into account not only the disease-effect (COPD),
but also the current smoking effect. Secondly, as COPD
is defined as a small airway disease, assessing the num-
ber of DC in this location yields more relevant results
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the central airways. Thirdly, the interrelationship of the
different myeloid DC markers was elucidated by flowcy-
tometry and crucial segregations were confirmed on
immunhistochemical staining. Finally, this study pro-
vides insight in new mechanisms that contribute to the
alterations in the composition of the DC population in
the small airways.
However, there are also several limitations to this
study which should be addressed.
Firstly, tissue was obtained from surgical resection speci-
mens from patients undergoing thoracotomy for solitary
pulmonary lesions. In theory, the presence of this patholo-
gic lesion could influence the number of DCs in the small
airways. However, samples were obtained at maximum
possible distance of this lesion, assuring the absence of
retro-obstructive pneumonia or tumour invasion. More-
over, all groups, except GOLD stage III&IV contained
patients with these lesions, minimizing their influence.
Secondly, the difference in gender ratio between the
study groups (with a higher proportion of women in the
never smoking group and a predominant male COPD
population) could influence the results of this study.
Recent publications suggest indeed a role for sex and
gender in the susceptibility and pathogenesis of COPD
[48]. However, significant associations between DC sub-
sets and FEV1 were not influenced by adjusting for gen-
der in the linear regression model, suggesting that our
findings regarding LDC and BDCA-1 DC are not due to
gender differences between groups.
Thirdly, the use of inhaled and systemic corticoster-
oids, especially in the most severe stages of COPD, could
influence the DC numbers and differentiation. Indeed,
several studies reported a decrease of circulating myeloid
BDCA-1+ DC in patients treated with systemic corticos-
teroids [49,50]. Moreover, inhaled corticosteroids
reduced the number of CD1a positive DCs in bronchial
biopsies of atopic asthma patients [36]. In contrast, use
of inhaled corticosteroids did not affect the number of
CD1a positive DCs in bronchial biopsies of COPD
patients [21]. Importantly, we demonstrated by linear
regression analysis that the number of LDC in the small
airways remained significantly associated with FEV1, even
after adjustment for possible confounders such as
the treatment with inhaled and oral corticosteroids. In
contrast, we found that FEV1 was no longer associated
with the number of BDCA-1 positive DC in lamina pro-
pria of the small airways when the treatment with corti-
costeroids was taken into account, suggesting that the
lower number of BDCA-1 positive DC observed in
COPD patients could at least be partially attributed to
the treatment with corticosteroids, as these medications
are mainly prescribed in the more severe stages of COPD.
Finally, identification of DC using immunohistochem-
ical staining for a single marker is hazardous as some
markers are also expressed on other cell types. For
instance, BDCA-1 is also expressed on B cells, whereas
DC-SIGN expression is also reported on macrophages.
Therefore, only cells with a morphology compatible
with a DC were regarded as positive cells.
Figure 11 Proposed mechanism of Dendritic Cell (DC) differentiation towards tissue resident DC in COPD. Langerhans-type DC originate
from their Blood Dendritic Cell Antigen 1 (BDCA-1)+ precursors under the influence of Transforming Growth Factor beta (TGFb), Tumor Necrosis
Factor Alpha (TNFa) and Activin-A. During this differentiation process, DC downregulate expression of BDCA-1. Enhanced differentiation towards
Langerhans-type DC is present in COPD, whereas the differentiation axis towards DC-SIGN positive interstitial type DC is not altered in COPD.
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This flowcytometric and immunohistochemical study
characterized for the first time pulmonary Langerhans-
type DC, which are related to their known BDCA-1+
precursors and which are segregated from interstitial-
type DC. In addition, we showed that DC differentiation
is altered in small airways of current smokers and
COPD patients with a selective accumulation of the
Langerhans-type DC, correlating with the expression of
Langerhans-type DC-inducing differentiation factor acti-
vin-A. This study identified the Langerhans-type DC
subset as an interesting focus for future research in
COPD pathogenesis.
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